Category: Ideas
-
Top 3 Tech Stocks That May Rocket Higher In Q2
in IdeasThe most oversold stocks in the information technology sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a…
-
What Does the Market Think About American Express?
in IdeasAmerican Express’s (NYSE:AXP) short percent of float has fallen 8.55% since its last report. The company recently reported that it has 7.64 million shares sold short, which is 1.39% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.55 days to cover their short positions on…
-
Wall Street’s Most Accurate Analysts Spotlight On 3 Utilities Stocks Delivering High-Dividend Yields
in IdeasDuring times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout. Benzinga readers can review the latest analyst takes on their favorite stocks by visiting Analyst Stock Ratings page. Traders can sort through…
-
These Defensives Could Rebound Despite Recession-Driven Bear Market: Analyst
in IdeasMost sectors are stumbling, but the more defensive corners of the S&P 500 are quietly setting up for a comeback. That’s according to JPMorgan’s Jason Hunter, who breaks the market into three camps: Former leaders (Tech, Consumer Discretionary, Financials) Cyclical sectors (Industrials, Materials, Energy), and Defensives (Healthcare, Staples, Utilities). The first two groups have cracked…
-
Wall Street’s Most Accurate Analysts Spotlight On 3 Tech Stocks Delivering High-Dividend Yields
in IdeasDuring times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout. Benzinga readers can review the latest analyst takes on their favorite stocks by visiting Analyst Stock Ratings page. Traders can sort through…
-
If You Invested $1000 In This Stock 20 Years Ago, You Would Have This Much Today
in IdeasW.W. Grainger (NYSE:GWW) has outperformed the market over the past 20 years by 7.08% on an annualized basis producing an average annual return of 14.83%. Currently, W.W. Grainger has a market capitalization of $45.83 billion. Buying $1000 In GWW: If an investor had bought $1000 of GWW stock 20 years ago, it would be worth…
-
How Do Investors Really Feel About American Airlines Group?
in IdeasAmerican Airlines Group’s (NYSE:AAL) short percent of float has fallen 3.34% since its last report. The company recently reported that it has 58.69 million shares sold short, which is 10.13% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions…
-
Top 3 Tech And Telecom Stocks You’ll Regret Missing This Month
in IdeasThe most oversold stocks in the communication services sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a…
-
Top 3 Utilities Stocks That May Rocket Higher This Quarter
in IdeasThe most oversold stocks in the utilities sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better…
-
Netflix, Vertex Pharmaceuticals And More On CNBC’s ‘Final Trades’
in IdeasOn CNBC’s “Halftime Report Final Trades,” Jim Lebenthal of Cerity Partners said he is long-term bullish but a bit nervous for the short term on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). RBC Capital analyst Brian Abrahams, on Feb. 20, maintained Vertex Pharmaceuticals with a Sector Perform rating and raised the price target from $407 to $408. Shannon…